Carlyle Group Inc. Phathom Pharmaceuticals, Inc. Transaction History
Carlyle Group Inc.
- $837 Million
- Q2 2024
A detailed history of Carlyle Group Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Carlyle Group Inc. holds 3,496,808 shares of PHAT stock, worth $61.3 Million. This represents 4.3% of its overall portfolio holdings.
Number of Shares
3,496,808
Previous 3,496,808
-0.0%
Holding current value
$61.3 Million
Previous $37.1 Million
3.01%
% of portfolio
4.3%
Previous 2.73%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
59MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$177 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$131 Million27.45% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$55.1 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$51.3 Million0.0% of portfolio
-
Jennison Associates LLC2.76MShares$48.3 Million0.02% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $686M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...